Fig. 4From: Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysisForest plots of pooled HRs of PFS and OS between the wild type and the TP53 mutation patients based on histopathological type of tumor (ADC or all NSCLC subtypes (a) PFS; (b) OS. Abbreviations: HR hazard ratio, PFS progression-free survival, OS overall survival, TP53 tumor protein 53, TKI tyrosine kinase inhibitor, ALK anaplastic lymphoma kinase, ADC adenocarcinoma, NSCLC non-small cell lung cancerBack to article page